Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 88 total PSOs listed by AHRQ.

PLEASE NOTE: To search for a PSO by State, use the 2 letter state abbreviation. Example: Kansas = KS

Ascension Healthcare Patient Safety Organization - P0111
Component of Parent Org(s):
  • Ascension
Effective Date and Time of Initial Listing: May 11, 2011 12:01 AM ET
PSO Mailing Address: 4600 Edmundson Road, St. Louis, MO 63134
PSO Phone Number: 314-733-8164
Point of Contact: Ruth Eaker
Point of Contact Phone: 314-733-8164
Point of Contact Email: Ruth.Eaker@ascension.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 05/11/2021 through 05/10/2023
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: Yes
USACS PSO - P0124
Component of Parent Org(s):
  • USACS Management Group
Effective Date and Time of Initial Listing: March 28, 2012 12:01 AM ET
PSO Mailing Address: 4535 Dressler Rd NW, Canton, OH 44718
PSO Phone Number: 330-493-4443
Point of Contact: Lisa Love
Point of Contact Phone: (330) 492-4559, ext. 1533
Point of Contact Email: lovel@usacs.com (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 03/28/2020 through 03/27/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No